Eurobio Scientific Overview
Pro stress-test →Eurobio Scientific is a major player in specialty in vitro diagnostics, offering diagnostic tests from research to commercialization in transplantation, immunology, and infectious diseases, with dedicated reagents for research laboratories including pharmaceutical and biotech companies. The company achieved 19% revenue growth in 2024 with €154.2 million in sales, establishing itself as a key player in European life sciences diagnostics.
Strategic Profile
Pro stress-test →The company has extensive distribution networks and a portfolio of proprietary products in molecular biology. Eurobio Scientific is executing strategic priorities including development of proprietary products, internationalization, and opening new markets to enable sustained sales and margin growth. As of December 2024, EB Development held 89.11% of share capital through strategic alignment with NextStage AM and IK Partners.
Competitive Landscape
Pro stress-test →Eurobio Scientific competes in specialty in vitro diagnostics across transplantation, immunology, and infectious disease segments. The company benefits from strong hospital relationships and proprietary molecular biology products. Main competitors include larger diagnostics players like Bio-Rad, Ortho Clinical Diagnostics, and specialized genomics firms in oncology diagnostics.
Industry Context
Eurobio Scientific operates in In Vitro Diagnostics (IVD) / Life Sciences.
Key facts
Founded: 1997 · Headquarters: Les Ulis, France · Employees: 320 · Revenue: €154.2M (2024) · Market cap: €238M